[U.S.] December 2021, CAFC, AstraZeneca v. Mylan

日本語原文 / Japanese original

Article information

Article type: Case note

Category: United States

Topics: —

First published on this website: 2026-11-01

Display and classification checked: November 2, 2026

Originally published on Ameblo: 2025-02-05 (Japan time). Full English translation.

https://ameblo.jp/hideki-takaishi/entry-12885213270.html

[U.S.] December 2021, CAFC, AstraZeneca v. Mylan

*Construction of the claim term “0.001% w/w”: the original judgment construed it as expressed to one significant figure (0.0005%–0.0014%).

⇒ Limitation satisfied

This judgment construed it as “0.00095%–0.00104%,” citing, among other reasons, the prosecution history of narrowing/deleting “about 0.0005 to about 0.05% w/w” to “0.001%.”

⇒ Limitation not satisfied

The Claim Scope Indicated by Digits after the Decimal Point Is Strongly Influenced by Intrinsic Evidence — Open Legal Community

Translator’s notes (editorial)

The source redundantly says “narrowed/deleted”; the reference to both is retained.

Consultation guide by purpose

Update history

The first-published date remains unchanged. Display maintenance, classification changes, related-article updates, and text corrections are recorded separately.

November 1, 2026: First published on this website.

November 2, 2026: Added article information, classification, topics, language navigation, related articles where the same case was confirmed, consultation guidance, and SEO. The original text and first-published date were preserved.